Question 1

What is CLN-978?

Accepted Answer

CLN-978 is a Other.

Question 2

How often does CLN-978 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was CLN-978 first tracked by Ergen?

Accepted Answer

First tracked on May 26, 2026.

Question 4

When was CLN-978 last mentioned in news?

Accepted Answer

Last active on May 26, 2026.

Question 5

What is CLN-978's current news sentiment?

Accepted Answer

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is CLN-978 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving CLN-978?

Accepted Answer

Cullinan Therapeutics Immunology Day Data (May 26, 2026, 7 articles).

Question 8

How did the "Cullinan Therapeutics Immunology Day Data" event impact CLN-978?

Accepted Answer

CLN-978 is a CD19xCD3 T cell engager being developed by Cullinan Therapeutics for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). New clinical data will be presented, potentially validating its efficacy.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.